Posted by Michael Wonder on 28 Feb 2026
Photocure partner Asieris announces that EMA has accepted marketing authorisation application for Cevira in Europe
27 February 2026 - Photocure announces that its partner Asieris Pharmaceuticals communicated today that its marketing authorisation application for Cevira (APL-1702) for the treatment of high-grade squamous intraepithelial lesions has been accepted by the EMA.
The marketing authorisation application submission to the EMA is primarily supported by results from the international multi-centre Phase 3 clinical trial of APL-1702, which enrolled over 20% European patients.
